Cellectar Biosciences Inc (NASDAQ: CLRB) has announced an extension of its continuing partnership with IntoCell Inc., a biotechnology company established in South Korea. Collaboration exceeds the necessary preclinical results The parties have been conjoining on uniting IntoCell’s authenticated unique Ortho-Hydroxy Protected Aryl Sulfate (OHPAS) linker chemistry with Cellectar’s authenticated original […]

Cellectar Biosciences Inc (NASDAQ: CLRB) entered into partnership with LegoChemBio to develop original first-in-class phospholipid medication conjugates. Improvement option is exercisable by both parties at defined points Under the contract, the two companies have the opportunity to jointly mature three new minor molecules exploiting Cellectar’s patented drug pointing platform, phospholipid […]